Literature DB >> 31872431

Soluble Aβ oligomers and protofibrils induce NLRP3 inflammasome activation in microglia.

Asta Lučiūnaitė1,2,3, Róisín M McManus2,3, Marija Jankunec4, Ildikó Rácz2, Cira Dansokho2,3, Indrė Dalgėdienė1, Stephanie Schwartz2, Frederic Brosseron3, Michael T Heneka2.   

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder causing memory loss, language problems and behavioural disturbances. AD is associated with the accumulation of fibrillar amyloid-β (Aβ) and the formation of neurofibrillary tau tangles. Fibrillar Aβ itself represents a danger-associated molecular pattern, which is recognized by specific microglial receptors. One of the key players is formation of the NOD-, LRR- and pyrin domain-containing 3 (NLRP3) inflammasome, whose activation has been demonstrated in AD patient brains and transgenic animal models of AD. Here, we investigated whether Aβ oligomers or protofibrils that represent lower molecular aggregates prior to Aβ deposition are able to activate the NLRP3 inflammasome and subsequent interleukin-1 beta (IL-1β) release by microglia. In our study, we used Aβ preparations of different sizes: small oligomers and protofibrils of which the structure was confirmed by atomic force microscopy. Primary microglial cells from C57BL/6 mice were treated with the respective Aβ preparations and NLRP3 inflammasome activation, represented by caspase-1 cleavage, IL-1β production, and apoptosis-associated speck-like protein containing a CARD speck formation was analysed. Both protofibrils and low molecular weight Aβ aggregates induced a significant increase in IL-1β release. Inflammasome activation was confirmed by apoptosis-associated speck-like protein containing a CARD speck formation and detection of active caspase-1. The NLRP3 inflammasome inhibitor MCC950 completely inhibited the Aβ-induced immune response. Our results show that the NLRP3 inflammasome is activated not only by fibrillar Aβ aggregates as reported before, but also by lower molecular weight Aβ oligomers and protofibrils, highlighting the possibility that microglial activation by these Aβ species may initiate innate immune responses in the central nervous system prior to the onset of Aβ deposition.
© 2019 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.

Entities:  

Keywords:  ASC speck; Alzheimer; IL-1β; NLRP3 inflammasome; microglia; s disease; soluble Aβ

Year:  2019        PMID: 31872431     DOI: 10.1111/jnc.14945

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  31 in total

Review 1.  Aß Pathology and Neuron-Glia Interactions: A Synaptocentric View.

Authors:  Christiaan F M Huffels; Jinte Middeldorp; Elly M Hol
Journal:  Neurochem Res       Date:  2022-08-17       Impact factor: 4.414

Review 2.  Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches.

Authors:  Clíona Farrell; Paige Mumford; Frances K Wiseman
Journal:  Front Neurosci       Date:  2022-06-07       Impact factor: 5.152

Review 3.  Targeting Microglia in Alzheimer's Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules.

Authors:  Ziyad M Althafar
Journal:  Molecules       Date:  2022-06-27       Impact factor: 4.927

4.  A Neuron, Microglia, and Astrocyte Triple Co-culture Model to Study Alzheimer's Disease.

Authors:  Celia Luchena; Jone Zuazo-Ibarra; Jorge Valero; Carlos Matute; Elena Alberdi; Estibaliz Capetillo-Zarate
Journal:  Front Aging Neurosci       Date:  2022-04-14       Impact factor: 5.702

Review 5.  Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases.

Authors:  Haruka Tsubaki; Ikuo Tooyama; Douglas Gordon Walker
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

Review 6.  How Microglia Manages Non-cell Autonomous Vicious Cycling of Aβ Toxicity in the Pathogenesis of AD.

Authors:  YunHee Seol; Soomin Ki; Hannah L Ryu; Sooyoung Chung; Junghee Lee; Hoon Ryu
Journal:  Front Mol Neurosci       Date:  2020-11-17       Impact factor: 5.639

Review 7.  Microglia in Alzheimer's Disease: A Target for Therapeutic Intervention.

Authors:  Guimei Zhang; Zicheng Wang; Huiling Hu; Meng Zhao; Li Sun
Journal:  Front Cell Neurosci       Date:  2021-11-24       Impact factor: 5.505

8.  Alzheimer Drug Trials: Combination of Safe and Efficacious Biologicals to Break the Amyloidosis-Neuroinflammation Vicious Cycle.

Authors:  Tamas Bartfai; Graham V Lees
Journal:  ASN Neuro       Date:  2020 Jan-Dec       Impact factor: 4.146

9.  Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression.

Authors:  Jessica E Rexach; Damon Polioudakis; Anna Yin; Vivek Swarup; Timothy S Chang; Tam Nguyen; Arjun Sarkar; Lawrence Chen; Jerry Huang; Li-Chun Lin; William Seeley; John Q Trojanowski; Dheeraj Malhotra; Daniel H Geschwind
Journal:  Cell Rep       Date:  2020-11-17       Impact factor: 9.423

Review 10.  The Impact of Systemic Inflammation on Alzheimer's Disease Pathology.

Authors:  Junhua Xie; Lien Van Hoecke; Roosmarijn E Vandenbroucke
Journal:  Front Immunol       Date:  2022-01-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.